About Intra-Cellular Therapies (NASDAQ:ITCI)
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. It is also developing ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ITCI
CUSIPN/A
Phone212-923-3344
Debt
Debt-to-Equity RatioN/A
Current Ratio33.04%
Quick Ratio33.04%
Price-To-Earnings
Trailing P/E Ratio-9.18
Forward P/E Ratio-5.84
P/E GrowthN/A
Sales & Book Value
Annual Sales$250,000.00
Price / Sales4,256.29
Cash FlowN/A
Price / CashN/A
Book Value$8.33 per share
Price / Book2.34
Profitability
EPS (Most Recent Fiscal Year)($2.12)
Net Income$-97,770,000.00
Net Margins-39,745.53%
Return on Equity-26.67%
Return on Assets-25.60%
Miscellaneous
Employees49
Outstanding Shares54,680,000
Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions
What is Intra-Cellular Therapies' stock symbol?
Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."
How were Intra-Cellular Therapies' earnings last quarter?
Intra-Cellular Therapies Inc (NASDAQ:ITCI) issued its quarterly earnings results on Thursday, March, 1st. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.06. The biopharmaceutical company had revenue of $5.06 million for the quarter, compared to analyst estimates of $0.05 million. Intra-Cellular Therapies had a negative return on equity of 26.67% and a negative net margin of 39,745.53%. The business's revenue was down 94.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.64) EPS. View Intra-Cellular Therapies' Earnings History.
When is Intra-Cellular Therapies' next earnings date?
What price target have analysts set for ITCI?
11 brokerages have issued 12-month price targets for Intra-Cellular Therapies' stock. Their forecasts range from $24.00 to $36.00. On average, they anticipate Intra-Cellular Therapies' share price to reach $29.10 in the next twelve months. View Analyst Ratings for Intra-Cellular Therapies.
What are Wall Street analysts saying about Intra-Cellular Therapies stock?
Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:
- 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (3/6/2018)
- 2. Cantor Fitzgerald analysts commented, "Lumateperone NDA filing still expected in mid-2018. We view the pre- NDA meeting (and what may be said thereafter), the actual filing and the FDA acceptance of it (presumably) as minor events that are expected and not stock moving." (3/1/2018)
- 3. SunTrust Banks analysts commented, "Meeting with FDA could help identify the path forward for ralinepag. On the 3Q17 results conference call, management commented that the company will seek a meeting with the FDA to determine the pivotal development plan for ralinepag. Specific timing of the meeting is pending FDA scheduling but management laid out their views on the drug candidate’s development program. Key considerations include 1) accelerating time to market, 2) maximizing the breadth and scope of label, 3) raising physician awareness of the compound and 4) comparing ralinepag with other available treatments." (11/8/2017)
Who are some of Intra-Cellular Therapies' key competitors?
Some companies that are related to Intra-Cellular Therapies include The Medicines (MDCO), Portola Pharmaceuticals (PTLA), Heron Therapeutics (HRTX), AnaptysBio (ANAB), Intercept Pharmaceuticals (ICPT), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Corcept Therapeutics (CORT), Motif (MTFB), Aimmune Therapeutics (AIMT), Insmed (INSM), Cambrex (CBM), MyoKardia (MYOK), Arena Pharmaceuticals (ARNA), Phibro Animal Health (PAHC), OPKO Health (OPK), Enanta Pharmaceuticals (ENTA) and Prestige Brands (PBH).
Who are Intra-Cellular Therapies' key executives?
Intra-Cellular Therapies' management team includes the folowing people:
- Dr. Sharon Mates Ph.D., Co-Founder, Chairman, CEO & Pres (Age 65)
- Mr. Lawrence J. Hineline CPA, VP of Fin., CFO, Treasurer & Assistant Sec. (Age 62)
- Dr. Robert E. Davis Ph.D., Sr. VP & Chief Scientific Officer (Age 67)
- Mr. Michael I. Halstead J.D., Sr. VP, Gen. Counsel, Corp. Compliance Officer & Sec. (Age 45)
- Dr. Kimberly E. Vanover Ph.D., Sr. VP of Clinical Devel. (Age 52)
Has Intra-Cellular Therapies been receiving favorable news coverage?
Press coverage about ITCI stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intra-Cellular Therapies earned a media sentiment score of 0.07 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 45.03 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Intra-Cellular Therapies?
Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intra-Cellular Therapies' stock price today?
One share of ITCI stock can currently be purchased for approximately $19.46.
How big of a company is Intra-Cellular Therapies?
Intra-Cellular Therapies has a market capitalization of $1.11 billion and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-97,770,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. Intra-Cellular Therapies employs 49 workers across the globe.
How can I contact Intra-Cellular Therapies?
Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-923-3344 or via email at [email protected]
MarketBeat Community Rating for Intra-Cellular Therapies (ITCI)
MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote "Outperform" if you believe ITCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Intra-Cellular Therapies (NASDAQ:ITCI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Intra-Cellular Therapies in the last 12 months. Their average twelve-month price target is $29.10, suggesting that the stock has a possible upside of 49.54%. The high price target for ITCI is $36.00 and the low price target for ITCI is $24.00. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.91 | 2.91 | 2.89 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $29.10 | $27.80 | $26.75 | $26.1429 |
| Price Target Upside: | 49.54% upside | 11.65% upside | 79.53% upside | 22.22% upside |
Intra-Cellular Therapies (NASDAQ:ITCI) Consensus Price Target History
Intra-Cellular Therapies (NASDAQ:ITCI) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Intra-Cellular Therapies (NASDAQ:ITCI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Intra-Cellular Therapies (NASDAQ ITCI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 19.80%
Institutional Ownership Percentage: 70.47%
Intra-Cellular Therapies (NASDAQ ITCI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/16/2018 | Lawrence J Hineline | VP | Sell | 49,700 | $20.02 | $994,994.00 | |  |
| 1/22/2018 | Michael Halstead | SVP | Sell | 25,500 | $18.03 | $459,765.00 | 191 | |
| 1/8/2018 | Kimberly E Vanover | SVP | Sell | 772 | $17.46 | $13,479.12 | 12,373 | |
| 1/8/2018 | Sharon Mates | Chairman | Sell | 6,604 | $17.48 | $115,437.92 | 1,088,707 | |
| 1/5/2018 | Kimberly E Vanover | SVP | Sell | 1,185 | $17.37 | $20,583.45 | 26,803 | |
| 1/5/2018 | Sharon Mates | Chairman | Sell | 11,257 | $17.08 | $192,269.56 | 1,099,964 | |
| 1/4/2018 | Lawrence J Hineline | CFO | Sell | 3,192 | $15.67 | $50,018.64 | 68,686 | |
| 12/29/2017 | Christopher D Alafi | Director | Buy | 1,001 | $14.48 | $14,494.48 | | |
| 12/11/2017 | Richard A Lerner | Director | Sell | 7,000 | $15.09 | $105,630.00 | 8,621 | |
| 12/5/2017 | Robert E Davis | SVP | Sell | 650 | $15.00 | $9,750.00 | 28,514 | |
| 11/22/2017 | Christopher D Alafi | Director | Buy | 10,000 | $15.55 | $155,500.00 | 744,466 | |
| 10/30/2017 | Sharon Mates | CEO | Sell | 18,750 | $15.75 | $295,312.50 | 1,107,457 | |
| 10/2/2017 | Alafi Capital Co Llc | Major Shareholder | Buy | 258,065 | $15.50 | $4,000,007.50 | 3,953,270 | |
| 1/5/2017 | Lawrence J Hineline | VP | Sell | 1,918 | $16.58 | $31,800.44 | 63,389 | |
| 1/5/2017 | Michael Halstead | SVP | Sell | 1,601 | $16.55 | $26,496.55 | 21,506 | |
| 1/5/2017 | Sharon Mates | Chairman | Sell | 4,081 | $16.55 | $67,540.55 | 1,088,707 | |
| 12/15/2016 | Kimberly E Vanover | SVP | Sell | 9,375 | $15.23 | $142,781.25 | 5,000 | |
| 12/7/2016 | Alafi Capital Co Llc | Major Shareholder | Buy | 65,000 | $16.27 | $1,057,550.00 | 3,674,379 | |
| 11/14/2016 | Christopher D Alafi | Director | Buy | 34,000 | $14.50 | $493,000.00 | 730,529 | |
| 2/29/2016 | Christopher D Alafi | Director | Buy | 100,000 | $29.70 | $2,970,000.00 | 728,828 | |
| 12/15/2015 | Lawrence J. Hineline | CFO | Sell | 45,000 | $51.45 | $2,315,250.00 | 62,200 | |
| 12/11/2015 | Sharon Mates | CEO | Sell | 51,500 | $53.87 | $2,774,305.00 | 1,086,185 | |
| 12/8/2015 | Joel S Marcus | Director | Sell | 92,700 | $54.47 | $5,049,369.00 | 18,722 | |
| 11/24/2015 | Lawrence J Hineline | CFO | Sell | 5,000 | $55.00 | $275,000.00 | 59,700 | |
| 6/8/2015 | Lawrence P Wennogle | VP | Sell | 25,000 | $26.84 | $671,000.00 | | |
| 3/11/2015 | Christopher D Alafi | Director | Buy | 625,000 | $24.00 | $15,000,000.00 | | |
| 12/9/2014 | Lawrence J Hineline | CFO | Sell | 22,500 | $16.71 | $375,975.00 | | |
| 12/1/2014 | Moshe Alafi | Major Shareholder | Buy | 1,422 | $14.75 | $20,974.50 | | |
| 11/28/2014 | Christopher D Alafi | Director | Buy | 35,000 | $14.75 | $516,250.00 | | |
| 11/19/2014 | Alafi Capital Co Llc | Major Shareholder | Buy | 1,034 | $14.25 | $14,734.50 | | |
| 11/18/2014 | Alafi Capital Co Llc | Major Shareholder | Buy | 3,664 | $14.26 | $52,248.64 | | |
| 11/13/2014 | Alafi Capital Co Llc | Major Shareholder | Buy | 12,200 | $15.34 | $187,148.00 | | |
| 11/6/2014 | Michael Halstead | SVP | Buy | 20,000 | $15.38 | $307,600.00 | | |
| 10/15/2014 | Lawrence P Wennogle | VP | Sell | 3,604 | $15.00 | $54,060.00 | | |
| 10/13/2014 | Lawrence P Wennogle | VP | Sell | 1,600 | $15.00 | $24,000.00 | | |
| 10/8/2014 | Lawrence P Wennogle | VP | Sell | 4,745 | $15.00 | $71,175.00 | | |
| 10/6/2014 | Lawrence P Wennogle | VP | Sell | 16,499 | $15.00 | $247,485.00 | | |
| 9/15/2014 | Lawrence P Wennogle | VP | Sell | 5,000 | $15.00 | $75,000.00 | | |
| 9/8/2014 | Lawrence J Hineline | CFO | Sell | 300 | $15.00 | $4,500.00 | | |
| 5/22/2014 | Lawrence P Wennogle | VP | Sell | 6,000 | $15.00 | $90,000.00 | | |
(Data available from 1/1/2013 forward)
Intra-Cellular Therapies (NASDAQ ITCI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Traders Buy Large Volume of Call Options on Intra-Cellular Therapies (ITCI)
www.americanbankingnews.com - April 19 at 8:32 AM |
| Intra-Cellular Therapies Sees Unusually Large Options Volume (ITCI)
www.americanbankingnews.com - April 19 at 8:32 AM |
 | Notable Tuesday Option Activity: ALGN, TWTR, ITCI
www.nasdaq.com - April 17 at 5:42 PM |
| Intra-Cellular Therapies Inc (ITCI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 11 at 7:35 PM |
| Intra-Cellular Therapies (ITCI) Given a $10.00 Price Target at Piper Jaffray
www.americanbankingnews.com - April 10 at 10:31 PM |
| Intra-Cellular Therapies (ITCI) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 10 at 1:11 PM |
| Intra-Cellular Therapies (ITCI) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 7 at 11:22 AM |
| Intra-Cellular Therapies Inc (ITCI) to Post FY2020 Earnings of ($2.01) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - April 5 at 9:17 AM |
 | Pre-Market Technical Scan on Biotech Equities -- INSYS Therapeutics, Intellia Therapeutics, Intercept Pharma, and ...
www.prnewswire.com - April 4 at 4:01 PM |
| Intra-Cellular Therapies (ITCI) Given a $25.00 Price Target at Leerink Swann
www.americanbankingnews.com - April 4 at 8:04 AM |
| Canaccord Genuity Analysts Give Intra-Cellular Therapies (ITCI) a $31.00 Price Target
www.americanbankingnews.com - April 3 at 10:36 AM |
 | Here's Why Alkermes plc and Intra-Cellular Therapies, Inc. Are Crashing Today
finance.yahoo.com - April 2 at 5:14 PM |
 | Pre-Market Technical Scan on Biotech Equities -- INSYS Therapeutics, Intellia Therapeutics, Intercept Pharma, and Intra-Cellular Therapies
www.bizjournals.com - April 2 at 9:00 AM |
 | Intra-Cellular down 7% premarket on FDA rejection of Alkermes' application for MDD med ALKS 5461
seekingalpha.com - April 2 at 9:00 AM |
| Intra-Cellular Therapies (ITCI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 1 at 1:36 PM |
| SunTrust Banks Upgrades Intra-Cellular Therapies (ITCI) to Buy
www.americanbankingnews.com - April 1 at 9:46 AM |
| BidaskClub Downgrades Intra-Cellular Therapies (ITCI) to Hold
www.americanbankingnews.com - March 30 at 11:07 AM |
| Intra-Cellular Therapies (ITCI) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - March 26 at 10:58 PM |
| Intra-Cellular Therapies (ITCI) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 24 at 1:37 PM |
| Intra-Cellular Therapies Inc (ITCI) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 17 at 7:38 PM |
| Intra-Cellular Therapies (ITCI) Lifted to Buy at BidaskClub
www.americanbankingnews.com - March 17 at 5:36 PM |
| Wired News – FDA Approved Intra-Cellular’s Rolling NDA Submission for Lumateperone for Schizophrenia
finance.yahoo.com - March 15 at 8:33 AM |
 | Intra-Cellular Therapies (ITCI) Announces Positive Pre-NDA Meeting with FDA for Lumateperone
www.streetinsider.com - March 13 at 7:05 PM |
| Canaccord Genuity Reiterates $31.00 Price Target for Intra-Cellular Therapies (ITCI)
www.americanbankingnews.com - March 13 at 3:46 PM |
| Intra-Cellular Therapies (ITCI) Announces Positive Pre-NDA Meeting with FDA for Lumateperone - StreetInsider.com
www.streetinsider.com - March 13 at 8:43 AM |
| Intra-Cellular Therapies Announces Positive Pre-NDA Meeting with FDA for Lumateperone for the Treatment of Schizophrenia
finance.yahoo.com - March 13 at 8:43 AM |
| Intra-Cellular Therapies (ITCI) Upgraded at ValuEngine
www.americanbankingnews.com - March 11 at 2:23 PM |
| Intra-Cellular Therapies Inc Forecasted to Earn FY2018 Earnings of ($3.95) Per Share (ITCI)
www.americanbankingnews.com - March 7 at 11:51 AM |
| Intra-Cellular Therapies' (ITCI) "Outperform" Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - March 7 at 10:59 AM |
| Intra-Cellular Therapies Inc (ITCI) Expected to Earn Q1 2018 Earnings of ($0.62) Per Share
www.americanbankingnews.com - March 7 at 7:55 AM |
| Equities Analysts Set Expectations for Intra-Cellular Therapies Inc's FY2019 Earnings (ITCI)
www.americanbankingnews.com - March 6 at 2:25 PM |
| SunTrust Banks Weighs in on Intra-Cellular Therapies Inc's FY2022 Earnings (ITCI)
www.americanbankingnews.com - March 5 at 9:50 AM |
| Intra-Cellular Therapies Inc to Post Q1 2018 Earnings of ($0.62) Per Share, Leerink Swann Forecasts (ITCI)
www.americanbankingnews.com - March 5 at 2:08 AM |
| Intra-Cellular Therapies (ITCI) Given Buy Rating at Cowen
www.americanbankingnews.com - March 3 at 8:22 PM |
| Intra-Cellular Therapies (ITCI) Rating Reiterated by SunTrust Banks
www.americanbankingnews.com - March 2 at 4:22 PM |
| Intra-Cellular Therapies' (ITCI) Buy Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - March 1 at 8:13 PM |
| Intra-Cellular Therapies (ITCI) Announces Quarterly Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - March 1 at 1:56 PM |
| Intra-Cellular Therapies reports Q4 results
seekingalpha.com - March 1 at 9:43 AM |
| Intra-Cellular Therapies (ITCI) Now Covered by JPMorgan Chase & Co.
www.americanbankingnews.com - February 26 at 2:20 PM |
| Intra-Cellular Therapies (ITCI) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - February 23 at 5:26 PM |
| Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast
finance.yahoo.com - February 22 at 8:34 AM |
| Intra-Cellular Therapies Inc (ITCI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - February 20 at 7:46 PM |
| Lawrence J. Hineline Sells 49,700 Shares of Intra-Cellular Therapies Inc (ITCI) Stock
www.americanbankingnews.com - February 20 at 6:40 PM |
| Intra-Cellular Therapies (ITCI) Upgraded to Sell by BidaskClub
www.americanbankingnews.com - February 19 at 3:56 PM |
| UPDATE - Intra-Cellular Therapies to Present at RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 15 at 5:10 PM |
| Intra-Cellular Therapies (ITCI) Now Covered by Royal Bank of Canada
www.americanbankingnews.com - February 11 at 3:24 PM |
| Intra-Cellular Therapies to Present at Upcoming Investor Conferences
finance.yahoo.com - February 7 at 9:52 AM |
| Intra-Cellular Therapies (ITCI) Cut to "Strong Sell" at BidaskClub
www.americanbankingnews.com - February 3 at 2:44 PM |
| Financial Contrast: Intra-Cellular Therapies (ITCI) and Mast Therapeutics (SVRA)
www.americanbankingnews.com - February 3 at 1:12 AM |
| Intra-Cellular Therapies Inc (ITCI) Short Interest Update
www.americanbankingnews.com - January 27 at 2:32 AM |
Intra-Cellular Therapies (NASDAQ:ITCI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Intra-Cellular Therapies (NASDAQ:ITCI) Income Statement, Balance Sheet and Cash Flow Statement
Intra-Cellular Therapies (NASDAQ ITCI) Stock Chart for Thursday, April, 19, 2018
Loading chart…
